Antiphospholipid and antioangiogenic activity in females with recurrent miscarriage and antiphospholipid syndrome

PELUSA HF; PEZZARINI, ELEONORA; BASIGLIO CL; MUSURUANA J; BEARZOTTI M; SVETAZ MJ; DANIELE, STELLA; BOTTAI, HEBE; ARRIAGA SM

ANNALS OF CLINICAL BIOCHEMISTRY

ROYAL SOC MEDICINE PRESS LTD

Lugar: LONDRES; Año: 2016

0004-5632

Background: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombosis, fetal losses and thrombocytopenia associated to antiphospholipid (APL) antibodies (Abs). They are directed to phospholipids, such as cardiolipins (a-cardiolipin, ACA) and lupus anticoagulant (LA), or to complexes formed by phospholipids and protein cofactors, such as β2 glycoprotein 1 (a-β2GP1) and annexin V (a-annexin V). These auto Abs may be considered as a family of Abs involved in thrombotic events and APL activity. On the other hand, some proangiogenic factors are involved in the normal development of placental vasculature, such as the vascular endothelial growth factor (VEGF). Overexpression of VEGF receptor in its soluble form (sVEGFR-1) has been associated to a higher antiangiogenic activity. Our aim was to analyze the association between ACA, LA, a-β2GP1, a-annexin V and sVEGFR-1 with recurrent miscarriage before week 10 of gestation in women with APS. Methods: We studied 24 women with primary or secondary APS, who were divided into two groups: women with recurrent miscarriage before week 10 of gestation [M; n=12] and women with no history of fetal loss [NM; n=12]. ACA, a-β2GP1, a-annexin V and sVEGF-R1 levels were assessed by ELISA, while LA was assessed by screening and confirmatory tests. Results: No significant association was observed between ACA, a-annexin V and sVEGF R-1 and either M or NM group (p>0.05). Contrarily, LA and a-β2GP1 were found to be significantly associated to the M group (p